• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 13.95
  • VXN 18.04
  • VXO -
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology. It focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. The company?s marketed products include ZEVALIN, a prescribed form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. Its late stage development products comprise apaziquone for the treatment of non-muscle invasive bladder cancer; and Belinostat, a histone deacytelase inhibitor for the treatment of various hematological and solid tumors. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

NO
     
SPPI (Spectrum Pharmaceuticals Inc)
Last Trade 9.39 Date 9/19/2019
Change % 0.76 % Price Change 0.07
Open 9.34 52 Week High 21.8
High 9.39 52 Week Low 6.22
Low 9.33 Type stock
Volume 6709 Average Volume 761725
Prev Close 9.32 Stock Exchange NASDAQ
Bid 9.34 Ask 9.39
Bid Size 4 Ask Size 4
1st Yr Estimated EPS Growth -0.2514 2nd Yr Estimated EPS Growth -1.0229
2 Years Forward Earning Yield 0.0032 2 Years Forward PE Ratio 310.6667
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 2.2576 Book Value Yield 0.2422
Buy Back Yield CAPE Ratio
Cash Return -0.1331 Cash Flow per Share -0.9273
Cash Flow Yield -0.0995 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.1878 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 38.3005 EV / Pre Tax Income
EV / Revenue 7.1113 EV / Total Asset 2.4096
Expected Dividend Growth Rate Free Cash Flow per Share -0.9641
Free Caash Flow Ratio Free Cash Flow Yield -0.1034
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.1406 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 4.128277 PB Ratio 10 Year Growth -0.003198
PB Ratio 3 Year Growth 4.239051 Cash Ratio 3 Year Average 562.6666
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 1.269755
Price to Cash Ratio 3.778274 Price / EBITDA
Price to Sales Ratio 9.147074 Price to Sales Ratio 10 Year Growth 0.01714
Price to Sales Ratio 3 Year Avg 8.48742 Price to Sales Ratio 5 Year Avg
Sale per Share 1.0189 Sales Yield 0.1093
Sustainable Growth Rate -0.5526 Tangible Book Value per Share 2.2576
Tangible Book Value per Share 3 year Avg 1.1854 Tangible Book Value per Share 5 year Avg 0.6896
Total Asset per Share 2.8591 Total Yield
Working Capital per Share 2.2068 Working Capital per Share 3 Year Avg 2.0069
Working Capital per Share 5 Year Avg 1.8782 Beta 3.551102